@DeanostockGood at least you adressed me this time around i can respect that.
So i will try to reply
with respect,
to reply to your thoughts even though i dont agree with much of what you say
Yes i understand how San Fran works i have spoken about this with Mark over the years Basically like speed dating but sat across the table from a potential investor
So the only thing i can take away from your first two paragraphs is that basically ANP wasted funds sending AF in the first instance, and AF was dead in the water before even starting out
You go on to say
So what could they do?
IMV it would seem that they are not leveraging the biggest funding resource they have in a proactive way but the reference to a "covert" visit you made may be a clue they are trying to.
GP will have connections who have connections back to VC companies and even wealthy individuals who need a riskier cornerstone opportunity in a beaten down sector.
So are you infering our biggest funding rescource are our chair and GP
Sorry Deano but you have got to be kidding me,
Where have you been these last two years
Both your major contacts suggested above with all the so called US MONEY behind them,
have been absolutely clueless in how to progress this through its finacial avenues,
if either either of them did, we would not be sat where we are today they would have stepped up to the plate and produced the funding for the Pivatol trial that was going to take us to market,
Please Deano, think about what you are saying its absolute nonsense im sorry to be so blunt.
You talk about a high probability of a plan and all the boxes ticked.
Tell me what was the pip study if it wasnt a set plan, infact it was a set plan to
marketing approval and drug sales,how much more of a plan do you actually require.
The only thing lacking was the funding to carry that plan to Fruition which all of a sudden you appear to think our two board members have mystically aquired the contacts to do so
LOL
They were there they didnt produce the funds then and they cannot produce the funding as we sit present day full stop
Look to GP he would be the last on my list from the debacle he has just removed himself from go ask a few of the LT holders of Neurobo how they feel about our major asset after being stripped of their wealth by his actions, and then walking away.
You are kidding me this is surely just a wind up Deano you cannot be serious !!
Ok Deano you got me, lol
You go on to say ANP havnt paid the price for entry as yet,
Sat on what was originally a pivatol trial to market and sales i would argue the trainig wheels are well and truly of.
Their innability to raise the funds was our only let down by those you appear to revere, lol
So after adressing the majority of what you say, let me back up a bit to your missunderstanding of my covert wording.
I conversations with Mark i have always maintained not enough information is given out to the Market as far as ANP go
I was please to see at the AGM a lot of this was outlined i did try desperately to connect through an open line at the AGM because i wanted to talk to various individuals at that meeting, if you watched you will hear our cfo at the end saying someone is trying to get through on the line that someone was myself,
Charmaine was very good i thought very articulate and spoke very well
i will not comment on Gil Price and his insights about funding,
but things looked promising ,
but IMHO have reverted back to the same old ANP carrying on in a covert way
I put it to the board to send AF on an extended trip to the US a carry on from the Biotech Conf in San fran, a public roadshow for all to see and this is not the first time i have asked as you will see below, but no they insist on keeping things
covert, how do you expect the outside investment world to know who we are if your own shareholders have no clue what is going on its a complete joke all around.
Is it just a case of not really
being in confidenceIs it just the fact that if they do go public and cannot deliver they can be answerable to their own inadequacies im not sure either way, just like the spark plus can be seen for what it is, rank ameturish to say the very least.
Deano like you, these are my thoughts only, of which over the years i have always conveyed to this board as a whole not just our CEO
For mine as a board i would keep Charmaine, integral part of the Co from a scientific and pipeline development point, George Vital part of the team with ref to patents and drug development, and Nuket again from the drug develoment point
The rest i would clear out and start a fresh new blood exciting and innovative thinkers that could adress our pathway forwards.
I give you an example in Joel Latham from IHL works to his strengths and adds value by onboarding those that can guide him through his weakneses
You talk about Nasdaq listing this guys tactics have been superb he is setting IHL for the recovery in the Biotech sector and boy when it recovers you watch this stock.
He is innovative, and this is where i believe ANP should be, hiring innovative personel
Joel went to NY to set up office in the US and coordinate the US listing and in one day an eager US investor bought up $7mil worth of stock on the ASX this is just one of many things he has achieved by knocking on doors and being dynamic.
You talk Deano as a defeatist as though it cannot be done,
With the correct people onboard this stock if trials succesful could well outshine the likes of Sarepta but they have to take on the market and be dynamic in their thinking i truly do not believe we have this at this moment in time.
Look belowAnother huge achievment by Joel Latham was getting onboard this guy
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of DirectorsHighlights:
• Highly experienced pharmaceutical executive with 20+ years at Pfizer and 10+ years at Novo Nordisk
• Secured FDA registration and marketing approval for 12 significant new drugs in the past 10 years at Novo Nordisk in his capacity of Vice President – US Regulatory Affairs
• Personal leadership of more than 15 successful US FDA Advisory Committee Meetings on behalf of Novo Nordisk and Pfizer
• Nationally recognized expert on FDA/EMA liaison interactions and US pharmaceutical
advertising and promotional practices
• Documented success with FDA accelerated approval programs including Fast-Track, Orphan Drug, Breakthrough Therapy Designations, and Priority Reviews.
Prior to joining Nova Nordisk, Mr Clark was Vice President of Worldwide Regulatory Strategy and US Regulatory Affairs at Pfizer, leading a team of up to 150 regional regulatory professionals supporting the drug development continuum. During his time at Pfizer, he led or supported FDA approval of many new medicines and represented Pfizer at critical interactions with FDA, and other global health authorities, including key project milestone meetings.
“Bob is amongst the best credentialed regulatory affairs experts in the world, and we’re delighted that he has joined our board of directors because it is a strong vote of confidence in our drug candidates and development strategy”, said Mr Joel Latham, CEO and Managing Director of Incannex.
“He brings to Incannex deep knowledge of the US regulatory environment and decades of experience at the highest level of large pharmaceutical organisations. His experience will be invaluable to us now that our interactions with FDA have become more frequent whilst we pursue our mission to bring cannabinoid and psychedelic pharmacological solutions to patients with unmet medical needs”.
Non-executive Director, Mr Robert B. Clark said,
“I look forward to working with the Board and the management team, and I am excited about the broad Incannex portfolio of products to treat patients who have few or no other available treatments. Cannabinoid and psychedelic pharmacotherapies represent a growing area of research and hold the potential to treat various conditions for which effective options are limited”.
I will finish by addingNovo Nordisk has a market cap of ~US$185 billion, and is one of the world’s biggest companies.How did Joel get this guy onboard probably because he is a persistant kind of guy who believes he can achieve, and like i said,
recognises his weaknesses, that being the move to the US, he now has a shining star to guide him through the regulatory pathways and from what i have seen of Joel guy he will take care of the finances to carry them forwards
WHYBecause he is capable full stopI pleaded with this board not to deviate from the PH 3 trial but to delay for six months go on a roadshow.
Meet up with advocacy groups and explain they are looking for a cure or an extention to their childrens lives, we have a drug that is showing signs of just that, the possibility of giving these boys a better quality of life by extending their mobility at least, with a great possibility of extending life expectancy,
So please help us raise these funds we require, reach out to the funds you are connected to help us so that in return we may help your children.
With this PH3 to market we are so close to helping them
but no it was a done deal nothing could change this board in their wisdom to back track,
because of their inability to raise the required amount to take this to fruitionand become what i still belive it can be
and that is a
BLOCKBUSTER drug and yes Deano i will put my hand up for one of those ridiculous valuations you talk of, of
$18.00 upon success and i validated my thoughts back then so wont bother going through it again
We have the right pipeline
we just dont have the right people
Thats allI could go on but this has probably bored the pants of folks anyway.
Deano has nothing to do with the price of entry which we have paid for in spades anyway
The data is there, confirmed by leaders in the field, and the European regulatory board in its acceptance in a trial to market which this board failed to take up
Its all to do with presentation and the presenteeuntill we find such a person im afraid its business as usual for me
See how we go
